Concepedia

Manja Friese‐Hamim

MF

Statistics

Publications

15

Citations

744

H-Index

15

Active since

2005

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

Syngene International (India)

Biocon (India)

HealthONE

The University of Texas MD Anderson Cancer Center

Manja Friese‐Hamim is an author at Merck KGaA, Darmstadt (Germany) specializing in pharmacology, oncology, and met inhibitors.

ORCID

Publications per year

2005–2021

15

Publications

15

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

Friedhelm Bladt, Bettina Faden, Manja Friese‐Hamim et al. · Clinical Cancer Research · 2013 · 144 citations · Full text

, , +15

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors

Dieter Dorsch, Oliver Schadt, Frank Stieber et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 89 citations · Full text

, , +12

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin et al. · Clinical Cancer Research · 2019 · 88 citations · Full text

, , +14

The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.

Manja Friese‐Hamim, Friedhelm Bladt, Giuseppe Locatelli et al. · PubMed · 2019 · 62 citations

, , +17

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models

Friedhelm Bladt, Manja Friese‐Hamim, Christian Ihling et al. · Cancers · 2014 · 61 citations · Full text

, , +17

1–5 of 15